Home › Trial NCT04095689
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
- Trial IDNCT04095689
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorThe Methodist Hospital Research Institute
- Enrollment8
- Start date2021-05-12
- ConditionsTriple Negative Breast Cancer · Anthracycline-refractory TNBC
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.